{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029259","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.724113+00:00","generated_at":"2026-06-13T18:54:03.472103+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Eledon shareholders approve 9.6M share increase to 2020 incentive plan at annual meeting","bullets":["Amended 2020 Long Term Incentive Plan: share reserve raised from 4.86M to 14.46M shares.","Two Class III directors re-elected: David-Alexandre C. Gros and Jan Hillson (each ~7.1M for votes).","Advisory say-on-pay passed with 7.05M for vs 234K against; auditor KMJ Corbin ratified with 9.62M for.","Plan extended through April 26, 2033; additional 9.6M shares approved by stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029259","json":"https://secwatch.observer/filing/0000950170-23-029259.json","markdown":"https://secwatch.observer/filing/0000950170-23-029259.md","text":"https://secwatch.observer/filing/0000950170-23-029259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/0000950170-23-029259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/eldn-20230621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:54:03.472103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bafcbc862c1b50280a1e86e2b31a5bc1e775759","claim":"Eledon Pharmaceuticals, Inc. shareholders approved Election of Class III Directors at the 2023-06-21 meeting.","evidence_excerpt":"Proposal 1: The stockholders of the Company elected each of David-Alexandre C. Gros, M.D. and Jan Hillson, M.D. as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2026 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/0000950170-23-029259-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"3c2f762b7334cdb585821e7d7c55738ea76b5c04","claim":"Eledon Pharmaceuticals, Inc. shareholders approved Approval of amendment to the 2020 Incentive Plan to increase shares available by 9,600,000 at the 2023-06-21 meeting.","evidence_excerpt":"Proposal 2: The stockholders of the Company approved an amendment to the Company's 2020 Incentive Plan, increasing the aggregate number of shares available for issuance by 9,600,000 shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/0000950170-23-029259-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"840f4a7498ba0c82993816992040bf24f1c7dcb0","claim":"Eledon Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-21 meeting.","evidence_excerpt":"Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2023 definitive proxy statement on Schedule 14A, as follows: For Against Abstain Broker Non-Vote 7,051,556 234,105 257,656 2,272,638","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/0000950170-23-029259-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"96217e8e2e102fc482210d07c8961aa6c63e39ab","claim":"Eledon Pharmaceuticals, Inc. shareholders approved Ratification of KMJ Corbin & Company LLP as independent registered public accounting firm at the 2023-06-21 meeting.","evidence_excerpt":"Proposal 4: The stockholders of the Company ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results of the stockholders' vote with respect to the ratification were as follows: For Against Abstain 9,624,236 187,115 4,604","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023029259/0000950170-23-029259-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}